Allogene upgraded by Citizens JMP with a new price target
$ALLO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 3/14/2025 | $5.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 8/8/2024 | $13.00 → $11.00 | Outperform | Oppenheimer |
| 5/31/2024 | $11.00 | Overweight | Piper Sandler |
| 1/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 1/5/2024 | Buy → Neutral | Guggenheim | |
| 12/8/2023 | $7.00 | Buy | Citigroup |
| 12/8/2023 | Buy | Citigroup |
Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response RateFour of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic PlatformPhase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Effic
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June. TD Cowen's 6th Annual Oncology Innovation Summit: Insights for ASCO & EHATuesday, May 279:30AM PT/12:30PM ET Jefferies Global Healthcare ConferenceWednesday, June 41:55PM PT/4:55PM ET Goldman Sachs 46th Annual Global Healthcare ConferenceTuesday, June 105:00AM PT/8:00AM ET Oppenheimer Innovators in I&I SummitWednesday, June 259:45AM PT/12:45PM ET
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois. An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC). Leveraging the proprietary Dagger® technology
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)